Up to 20% of people above the age of 65 years suffer from an abnormal decline in memory and related brain functions. This condition, mild cognitive impairment (MCI), substantially decreases the quality of life of the affected and presents an emotional and financial burden to their loved ones, who typically perform informal care. Unfortunately, MCI currently has no approved treatment. With myne, we aim to put the latest advances in personalized neuromodulation directly into the hands of users suffering from MCI. After initially obtaining the frequency of brainwaves using behavioral input alone, myne can then deliver personalized brain stimulation.

This is achieved by playing sequences of sounds, heard simply through a conventional pair of headphones, without requiring any additional devices. State-of-the-art research shows that personalized electric brain stimulation can, using expensive laboratory equipment and trained experts, improve memory performance. With myne, we want to make these benefits available to users from the comfort of their own homes and using just their smartphones.

While the unique technology underlying the personalization in myne is currently undergoing validation, our team has already shown the critical importance of personalizing the neuromodulation to improve the memory of healthy individuals. Within the next year, we expect to significantly improve the speed of personalization, demonstrate the clinical feasibility of this novel neuromodulation approach in the MCI population and develop an initial minimum viable product for usability testing.

myne is being built by experts in brain stimulation and psychiatry working at the interface between research and clinical practice. In the future, myne aims to become a platform for deviceless, personalized auditory neuromodulation and thereby enable the benefits of personalized neuromodulation to leave the lab and become scalable and accessible solutions that benefit patients with brain disorders.